Following quite encouraging news from the laboratory on Monday, Amgen (NASDAQ: AMGN) was something of a stock market favorite the following day. Its shares closed the trading session more than 4% ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an eight-week period.

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of MariTide.

The dust is beginning to settle after the Edmonton Oilers lost in the Stanley Cup Final for the second year in a row. And of course, when you take a step back, there are some silver linings, and ...

Ponomarev signed a three-year contract with the KHL's Avangard Omsk on Wednesday, per Seth Rorabaugh of Tribune-Review Sports. Ponomarev had 15 goals, 41 points and 44 PIM across 55 regular-season ...

Pittsburgh Penguins forward prospect Vasily Ponomarev has signed a three-year contract with Avangard Omsk of Russia’s Kontinental Hockey League (KHL). That team announced the transaction via ...

The International Boxing Federation (IBF) received official notification on June 5, that Vasily Lomachenko was retiring from the sport of boxing, thereby relinquishing his title as IBF Lightweight ...

Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs to offset losses. Learn why AMGN stock is a Buy.

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has eked out another legal win.

Deep-pocketed investors have adopted a bearish approach towards Amgen AMGN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Amgen, based in Thousand Oaks, California, first broke ground in New Albany in 2021. Here's how the company plans to expand.